Goldman Sachs Group Inc Aadi Bioscience, Inc. Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024
BUY
$1.46 - $2.31 $152,848 - $241,836
104,691 Added 211.16%
154,270 $225,000
Q1 2024

May 15, 2024
BUY
$1.59 - $2.44 $78,830 - $120,972
49,579 New
49,579 $116,000
Q2 2023

May 14, 2024
BUY
$6.84 - $8.56 $3,549 - $4,442
519 Added 2.1%
25,215 $172,000
Q2 2023

Aug 14, 2023
BUY
$6.84 - $8.56 $3,549 - $4,442
519 Added 2.1%
25,215 $172,000
Q1 2023

May 14, 2024
SELL
$6.85 - $13.0 $18,104 - $34,359
-2,643 Reduced 9.67%
24,696 $178,000
Q1 2023

May 11, 2023
SELL
$6.85 - $13.0 $18,104 - $34,359
-2,643 Reduced 9.67%
24,696 $178,000
Q4 2022

May 14, 2024
BUY
$11.99 - $14.5 $18,740 - $22,663
1,563 Added 6.06%
27,339 $350,000
Q4 2022

Feb 13, 2023
BUY
$11.99 - $14.5 $18,740 - $22,663
1,563 Added 6.06%
27,339 $350,000
Q3 2022

May 14, 2024
SELL
$12.03 - $14.22 $215,168 - $254,338
-17,886 Reduced 40.96%
25,776 $364,000
Q3 2022

Nov 10, 2022
SELL
$12.03 - $14.22 $215,168 - $254,338
-17,886 Reduced 40.96%
25,776 $364,000
Q2 2022

May 14, 2024
BUY
$11.57 - $17.92 $505,169 - $782,423
43,662 New
43,662 $538,000
Q2 2022

Aug 15, 2022
SELL
$11.57 - $17.92 $183,789 - $284,659
-15,885 Reduced 26.68%
43,662 $538,000
Q1 2022

May 16, 2022
BUY
$16.65 - $24.97 $991,457 - $1.49 Million
59,547 New
59,547 $1.01 Million

Others Institutions Holding AADI

# of Institutions
55
Shares Held
12.6M
Call Options Held
23.8K
Put Options Held
0
View Full List

About Aadi Bioscience, Inc.

AADI Quotes by TradingView
  • Ticker AADI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 21,016,800
  • Market Cap $48.3M
  • Description
  • Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...
More about AADI
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email